Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
The hopes of millions of middle-aged British men - and women - were dashed yesterday, as doctors dismissed the idea of a male menopause, and said testosterone patches were no solution to a mid-life crisis.
GPs fear a deluge of patients demanding the new patches, launched today, which alleviate the problems of declining testosterone levels, including loss of libido, impotence, fatigue, loss of muscle power, and depression.
The male menopause has been touted as the cause of these symptoms. Many men hoped that testosterone hormone replacement therapy would have the same rejuvenating effect on them as oestrogen patches do on women. But at a conference on the Andropatch yesterday, Dr Ian Banks, a part- time GP, said there was no evidence in men of an equivalent of the female menopause. Healthy males do not have a dramatic drop in testosterone levels in middle-age.
"What we do know about middle age is that it is a time of uncertainty and failing confidence, with an inability to fit the media image of a sexually powerful, competitive, macho male, compounded by the fear of ageing," Dr Banks, a middle-aged man, said. "It is tempting to ... put all this down to a lack of sex hormone." The belief that the patches were "an elixir of life" did a grave disservice to the public - and the health service," he said. The patches will cost the NHS around pounds 45 a month per patient, and tests prior to prescription will cost at least pounds 30.
The Andropatch will benefit between 20,00-30,000 men who suffer from hypogonadism (testosterone deficiency). Dr Richard Foulds, medical director of the manufacturer, SmithKline Beecham Pharmaceuticals, said they wanted to encourage a responsible attitude towards prescribing the patches. However, executives know they have struck a goldmine. The idea of the male menopause has become fixed in the minds of many men who see no reason why they should not receive a testosterone boost.
Leading article, page 15
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments